{"id":30902,"date":"2025-03-29T21:25:26","date_gmt":"2025-03-29T13:25:26","guid":{"rendered":"https:\/\/flcube.com\/?p=30902"},"modified":"2025-03-29T21:25:28","modified_gmt":"2025-03-29T13:25:28","slug":"guangdong-accelerates-centralized-procurement-for-apixaban-and-key-therapeutics","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=30902","title":{"rendered":"Guangdong Accelerates Centralized Procurement for Apixaban and Key Therapeutics"},"content":{"rendered":"\n<p>The Guangdong Drug Trading Center has issued a critical update on preparations for the centralized volume-based procurement (VBP) of Apixaban Tablets and related medications under the Guangdong Alliance framework. This initiative, aligned with provincial healthcare policies (Yue Medical Insurance Letter [2025] No. 49), mandates streamlined logistics and supply chain coordination to ensure uninterrupted access to essential therapies.<\/p>\n\n\n\n<p><strong>Key Implementation Steps for Stakeholders<\/strong><\/p>\n\n\n\n<ol start=\"1\" class=\"wp-block-list\">\n<li><strong>Procurement Volume Verification<\/strong>:<br>Healthcare institutions and selected suppliers must log into the Guangdong Bidding and Procurement Subsystem (via CA authentication) to review assigned procurement quotas under \u201cDrug Transactions > Catalog Management > Hospital Agreement Volume.\u201d<\/li>\n\n\n\n<li><strong>Distribution Network Setup<\/strong>:<br>Manufacturers of winning\/volume-limited products (listed in the attached catalog) are required to establish\u914d\u9001 relationships through the subsystem\u2019s \u201cDrug Transactions > Distribution Management (Production)\u201d module. Operational guidelines are available on the platform\u2019s \u201cMember Services > Guides\u201d section.<\/li>\n\n\n\n<li><strong>Compliance and Supply Assurance<\/strong>:\n<ul class=\"wp-block-list\">\n<li>Manufacturers bear primary responsibility for quality control and delivery reliability, ensuring coverage across all participating medical institutions.<\/li>\n\n\n\n<li>Proactive inventory management is urged to prevent supply disruptions.<\/li>\n<\/ul>\n<\/li>\n<\/ol>\n\n\n\n<p><strong>Strategic Implications for the Pharmaceutical Industry<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Cost Efficiency<\/strong>: The VBP model reinforces price negotiation, likely pressuring margins but expanding market access for compliant firms.<\/li>\n\n\n\n<li><strong>Operational Agility<\/strong>: Enhanced distribution requirements demand robust logistics partnerships and real-time monitoring systems.<\/li>\n\n\n\n<li><strong>Quality Compliance<\/strong>: Stricter oversight underscores the need for GMP adherence and post-market surveillance.<\/li>\n<\/ul>\n\n\n\n<p><strong>Contact Information<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Online support via the Guangdong Drug Trading Center\u2019s official website.<\/li>\n\n\n\n<li>Hotline: 0086-20-29195621 \/ 0086-20-38036197 (Weekdays: 8:30\u201312:00, 14:00\u201317:30).<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/li>\n<\/ul>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The Guangdong Drug Trading Center has issued a critical update on preparations for the centralized&#8230;<\/p>\n","protected":false},"author":1,"featured_media":30903,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[4],"tags":[82],"class_list":["post-30902","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-policy-regulatory","tag-vbp-voluem-based-procurement"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Guangdong Accelerates Centralized Procurement for Apixaban and Key Therapeutics - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"The Guangdong Drug Trading Center has issued a critical update on preparations for the centralized volume-based procurement (VBP) of Apixaban Tablets and related medications under the Guangdong Alliance framework. This initiative, aligned with provincial healthcare policies (Yue Medical Insurance Letter [2025] No. 49), mandates streamlined logistics and supply chain coordination to ensure uninterrupted access to essential therapies.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=30902\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Guangdong Accelerates Centralized Procurement for Apixaban and Key Therapeutics\" \/>\n<meta property=\"og:description\" content=\"The Guangdong Drug Trading Center has issued a critical update on preparations for the centralized volume-based procurement (VBP) of Apixaban Tablets and related medications under the Guangdong Alliance framework. This initiative, aligned with provincial healthcare policies (Yue Medical Insurance Letter [2025] No. 49), mandates streamlined logistics and supply chain coordination to ensure uninterrupted access to essential therapies.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=30902\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-29T13:25:26+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-03-29T13:25:28+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/2905-png.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30902#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30902\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Guangdong Accelerates Centralized Procurement for Apixaban and Key Therapeutics\",\"datePublished\":\"2025-03-29T13:25:26+00:00\",\"dateModified\":\"2025-03-29T13:25:28+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30902\"},\"wordCount\":245,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30902#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/2905-png.webp\",\"keywords\":[\"VBP (voluem-based procurement)\"],\"articleSection\":[\"Policy \\\/ Regulatory\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=30902#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30902\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=30902\",\"name\":\"Guangdong Accelerates Centralized Procurement for Apixaban and Key Therapeutics - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30902#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30902#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/2905-png.webp\",\"datePublished\":\"2025-03-29T13:25:26+00:00\",\"dateModified\":\"2025-03-29T13:25:28+00:00\",\"description\":\"The Guangdong Drug Trading Center has issued a critical update on preparations for the centralized volume-based procurement (VBP) of Apixaban Tablets and related medications under the Guangdong Alliance framework. This initiative, aligned with provincial healthcare policies (Yue Medical Insurance Letter [2025] No. 49), mandates streamlined logistics and supply chain coordination to ensure uninterrupted access to essential therapies.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30902#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=30902\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30902#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/2905-png.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/2905-png.webp\",\"width\":1080,\"height\":608,\"caption\":\"Guangdong Accelerates Centralized Procurement for Apixaban and Key Therapeutics\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30902#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Guangdong Accelerates Centralized Procurement for Apixaban and Key Therapeutics\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Guangdong Accelerates Centralized Procurement for Apixaban and Key Therapeutics - Insight, China&#039;s Pharmaceutical Industry","description":"The Guangdong Drug Trading Center has issued a critical update on preparations for the centralized volume-based procurement (VBP) of Apixaban Tablets and related medications under the Guangdong Alliance framework. This initiative, aligned with provincial healthcare policies (Yue Medical Insurance Letter [2025] No. 49), mandates streamlined logistics and supply chain coordination to ensure uninterrupted access to essential therapies.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=30902","og_locale":"en_US","og_type":"article","og_title":"Guangdong Accelerates Centralized Procurement for Apixaban and Key Therapeutics","og_description":"The Guangdong Drug Trading Center has issued a critical update on preparations for the centralized volume-based procurement (VBP) of Apixaban Tablets and related medications under the Guangdong Alliance framework. This initiative, aligned with provincial healthcare policies (Yue Medical Insurance Letter [2025] No. 49), mandates streamlined logistics and supply chain coordination to ensure uninterrupted access to essential therapies.","og_url":"https:\/\/flcube.com\/?p=30902","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-03-29T13:25:26+00:00","article_modified_time":"2025-03-29T13:25:28+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/2905-png.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=30902#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=30902"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Guangdong Accelerates Centralized Procurement for Apixaban and Key Therapeutics","datePublished":"2025-03-29T13:25:26+00:00","dateModified":"2025-03-29T13:25:28+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=30902"},"wordCount":245,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=30902#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/2905-png.webp","keywords":["VBP (voluem-based procurement)"],"articleSection":["Policy \/ Regulatory"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=30902#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=30902","url":"https:\/\/flcube.com\/?p=30902","name":"Guangdong Accelerates Centralized Procurement for Apixaban and Key Therapeutics - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=30902#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=30902#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/2905-png.webp","datePublished":"2025-03-29T13:25:26+00:00","dateModified":"2025-03-29T13:25:28+00:00","description":"The Guangdong Drug Trading Center has issued a critical update on preparations for the centralized volume-based procurement (VBP) of Apixaban Tablets and related medications under the Guangdong Alliance framework. This initiative, aligned with provincial healthcare policies (Yue Medical Insurance Letter [2025] No. 49), mandates streamlined logistics and supply chain coordination to ensure uninterrupted access to essential therapies.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=30902#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=30902"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=30902#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/2905-png.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/2905-png.webp","width":1080,"height":608,"caption":"Guangdong Accelerates Centralized Procurement for Apixaban and Key Therapeutics"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=30902#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Guangdong Accelerates Centralized Procurement for Apixaban and Key Therapeutics"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/2905-png.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/30902","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=30902"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/30902\/revisions"}],"predecessor-version":[{"id":30904,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/30902\/revisions\/30904"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/30903"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=30902"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=30902"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=30902"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}